Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Robert J. MayerRoger B. DavisCharles A. SchifferDeborah BergBayard L. PowellPhilip SchulmanGeorge OmuraJoseph O. MooreO. Ross McIntyreE Frei
Abstract
These data support the concept of a dose-response effect for cytarabine in patients with AML who are 60 years of age or younger. The results with the high-dose schedule in this age group are comparable to those reported in similar patients who have undergone allogeneic bone marrow transplantation during a first remission.
Metrics
Citation History
Topics
Related Documents
Intensive postremission chemotherapy in Taiwanese adults with acute myelogenous leukemia
Hui‐Chi HsuJyh‐Pyng GauJacqueline Ming LiuWing‐Keung ChauChao‐Hung Ho
Postremission therapy in adults with acute myeloid leukemia
Long-Term Outcome of Postremission Chemotherapy for Adults with Acute Myeloid Leukemia Using Different Dose-Intensities
Sequential Pilot Studies of Intensive Postremission Chemotherapy for Acute Nonlymphocytic Leukemia
M. C. PettiGiuseppe AvvisatiAgostino TafuriGiovanna MeloniSergio AmadoriFranco Mandelli
Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
A. W. DekkerMars B. vanʼt VeerW SizooH. L. HaakJ. van der LelieG. J. OssenkoppeleP.C. HuijgensH. SchoutenPieter SonneveldRoel WillemzeLF VerdonckW L van PuttenBob Löwenberg